Sichenzia Ross Friedman Ference LLP Represents Amarantus BioScience Holdings, Inc. in a $3 Million Registered Direct Offering
February 24, 2016 – New York, NY – Press Release – Sichenzia Ross Friedman Ference LLP announced today that the Firm represented Amarantus BioScience Holdings, Inc. in a $3 million offering of the Company’s Series H Convertible Preferred Stock and Warrants to purchase common stock.
Chardan Capital Markets, LLC acted as sole placement agent for the transaction.
The securities were offered pursuant to an effective shelf registration statement.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey Fessler and Marcelle Balcombe.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference Partner Jay Kaplowitz Quoted in Washington Post Article - October 18, 2018
- Sichenzia Ross Ference LLP Acts as General Counsel in Rusoro Mining Limited’s $1.28 Billion Settlement with Venezuela - October 15, 2018
- Sichenzia Ross Ference LLP Represents Rodman & Renshaw a Unit of H.C Wainwright in a $15 Million Upsized Public Offering of Medical Transcript Billing, Corp. - October 15, 2018